Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVRONASDAQ:CADLNASDAQ:CMPXNASDAQ:HUMA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVROAVROBIO$9.98$0.88▼$1.65$62.85M1.23269,831 shs206,800 shsCADLCandel Therapeutics$4.79-1.2%$5.18$3.79▼$14.60$240.04M-0.871.47 million shs228,612 shsCMPXCompass Therapeutics$2.65+1.0%$2.10$0.77▼$4.08$366.87M1.42956,040 shs286,105 shsHUMAHumacyte$2.16-3.4%$2.02$1.15▼$9.79$333.35M1.993.81 million shs534,732 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVROAVROBIO0.00%0.00%0.00%0.00%0.00%CADLCandel Therapeutics+3.85%-1.82%-10.68%-35.33%-21.14%CMPXCompass Therapeutics+3.15%+19.63%+25.36%+28.43%+136.04%HUMAHumacyte+0.90%-4.29%-11.86%+11.50%-56.27%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVROAVROBION/AN/AN/AN/AN/AN/AN/AN/ACADLCandel Therapeutics2.4772 of 5 stars3.53.00.00.02.30.80.6CMPXCompass Therapeutics2.9724 of 5 stars4.61.00.00.00.05.00.0HUMAHumacyte2.1356 of 5 stars3.51.00.00.01.52.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVROAVROBIO 0.00N/AN/AN/ACADLCandel Therapeutics 3.00Buy$21.00338.41% UpsideCMPXCompass Therapeutics 3.11Buy$13.13396.22% UpsideHUMAHumacyte 3.00Buy$11.71443.59% UpsideCurrent Analyst Ratings BreakdownLatest AVRO, CADL, CMPX, and HUMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.005/14/2025HUMAHumacyteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$4.005/14/2025HUMAHumacyteBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$17.00 ➝ $14.005/13/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.005/9/2025CMPXCompass TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $10.004/28/2025CMPXCompass TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.004/22/2025CMPXCompass TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/21/2025CMPXCompass TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $24.004/21/2025CMPXCompass TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.004/11/2025CADLCandel TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.00 ➝ $19.004/4/2025CMPXCompass TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$10.00 ➝ $24.00(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVROAVROBION/AN/AN/AN/A$2.13 per shareN/ACADLCandel Therapeutics$120K1,999.94N/AN/A$1.41 per share3.40CMPXCompass Therapeutics$850K430.30N/AN/A$0.91 per share2.91HUMAHumacyte$517K646.58N/AN/A($0.41) per share-5.26Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVROAVROBIO$12.16M$0.692.03N/AN/AN/A-50.52%-47.13%N/ACADLCandel Therapeutics-$55.18M-$1.34N/AN/AN/AN/A-136.74%-63.13%8/12/2025 (Estimated)CMPXCompass Therapeutics-$49.38M-$0.41N/AN/AN/AN/A-42.47%-38.31%8/11/2025 (Estimated)HUMAHumacyte-$148.70M-$0.69N/AN/AN/AN/AN/A-73.59%8/12/2025 (Estimated)Latest AVRO, CADL, CMPX, and HUMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025CADLCandel Therapeutics-$0.24$0.13+$0.37$0.13N/AN/A5/13/2025Q1 2025HUMAHumacyte-$0.19-$0.10+$0.09$0.28$0.46 million$0.52 million5/8/2025Q1 2025CMPXCompass Therapeutics-$0.12-$0.12N/A-$0.12N/AN/A3/28/2025Q4 2024HUMAHumacyte-$0.23-$0.16+$0.07-$0.16$0.64 million$7.23 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVROAVROBION/AN/AN/AN/AN/ACADLCandel TherapeuticsN/AN/AN/AN/AN/ACMPXCompass TherapeuticsN/AN/AN/AN/AN/AHUMAHumacyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVROAVROBION/A26.1726.17CADLCandel Therapeutics0.014.644.64CMPXCompass TherapeuticsN/A8.338.33HUMAHumacyte0.363.683.28Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVROAVROBIO62.63%CADLCandel Therapeutics13.93%CMPXCompass Therapeutics68.43%HUMAHumacyte44.71%Insider OwnershipCompanyInsider OwnershipAVROAVROBIO9.20%CADLCandel Therapeutics16.60%CMPXCompass Therapeutics29.80%HUMAHumacyte5.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVROAVROBIO1344.89 million40.76 millionOptionableCADLCandel Therapeutics6050.10 million41.79 millionOptionableCMPXCompass Therapeutics20138.28 million97.08 millionNot OptionableHUMAHumacyte150155.12 million147.21 millionOptionableAVRO, CADL, CMPX, and HUMA HeadlinesRecent News About These CompaniesHumacyte, Inc. (HUMA) Gains As Market Dips: What You Should KnowJune 18, 2025 | msn.comHumacyte, Inc. (NASDAQ:HUMA) Receives $11.71 Consensus Price Target from BrokeragesJune 15, 2025 | americanbankingnews.comHumacyte (NASDAQ:HUMA) Downgraded by Wall Street Zen to SellJune 14, 2025 | marketbeat.comHumacyte, Inc. (NASDAQ:HUMA) Given Consensus Rating of "Buy" by AnalystsJune 12, 2025 | marketbeat.comHumacyte: Revenue Ramp From Symvess IncomingJune 11, 2025 | seekingalpha.comCantor Fitzgerald Predicts Humacyte FY2026 EarningsJune 10, 2025 | marketbeat.comD. Boral Capital Reaffirms Buy Rating for Humacyte (NASDAQ:HUMA)June 9, 2025 | marketbeat.comResults from Humacyte’s V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery MeetingJune 9, 2025 | theglobeandmail.comResults from Humacyte's V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery MeetingJune 9, 2025 | globenewswire.comHumacyte Paradoxically Scales Back As Symvess Begins Its Long JourneyJune 9, 2025 | seekingalpha.comHumacyte, Inc. (NASDAQ:HUMA) Short Interest Up 20.7% in MayJune 4, 2025 | marketbeat.comNuveen Asset Management LLC Lowers Stake in Humacyte, Inc. (NASDAQ:HUMA)June 4, 2025 | marketbeat.comTommy Tuberville traded these 4 stocks at the perfect time: Why they raised red flagsJune 4, 2025 | msn.comHumacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3June 2, 2025 | globenewswire.comHumacyte, Inc. (NASDAQ:HUMA) Shares Bought by Bank of America Corp DEJune 1, 2025 | marketbeat.comIs Humacyte, Inc. (HUMA) a Buy as Wall Street Analysts Look Optimistic?May 30, 2025 | finance.yahoo.comMillennium Management LLC Sells 348,653 Shares of Humacyte, Inc. (NASDAQ:HUMA)May 30, 2025 | marketbeat.comHumacyte, Inc. (NASDAQ:HUMA) Shares Sold by Voloridge Investment Management LLCMay 29, 2025 | marketbeat.comHumacyte, Inc. (NASDAQ:HUMA) Holdings Decreased by Two Sigma Investments LPMay 29, 2025 | marketbeat.comWaverly Advisors LLC Buys 211,009 Shares of Humacyte, Inc. (NASDAQ:HUMA)May 25, 2025 | marketbeat.comHumacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NasdaqMay 19, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAVRO, CADL, CMPX, and HUMA Company DescriptionsAVROBIO NASDAQ:AVROAVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Candel Therapeutics NASDAQ:CADL$4.79 -0.06 (-1.24%) As of 11:31 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.Compass Therapeutics NASDAQ:CMPX$2.64 +0.03 (+0.95%) As of 11:31 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.Humacyte NASDAQ:HUMA$2.15 -0.08 (-3.36%) As of 11:32 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Costco at a Crossroads: Is the Next Move Higher or Lower? AST SpaceMobile's Signal Strengthens as Stock Nears Orbit Oracle Stock Boils Higher, $300 Price Target in Sight 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Which Analyst-Favorite Drone Stock Will Come Out on Top? Why Qualcomm’s Latest Price Target Can't Be Ignored Texas Instruments Stock: Congress Likes It, Should You Too? Geospace Stock Skyrockets After Major Petrobras Contract Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
